NIH

Last year, Cellecta received a Phase 1 NIH SBIR grant to develop validated single guide RNA (sgRNA). The initial study was designed to investigate an approach to optimize CRISPR sgRNA to improve the efficiency of CRISPR knockout.The 5'-end of the CRISPR sgRNA contains 20 nucleotides specific to the gene targeted...

Cellecta received a Phase I NIH SBIR Grant to develop CRISPR guide RNAs (gRNAs or sgRNAs) for human and mouse genes and then use these to build a knockout library targeting 6,500 key disease-related genes in major signal transduction pathways.Targeting a gene for knockout using CRISPR requires a short strand of...

It's been a while since the last post to this blog. It is not that nothing has been going on, in fact, quite the opposite. It has been quite busy the past several months and, unfortunately, blog postings have suffered. However, I thought I would get things started again with short post about our recent SBIR...

We recently received a phase II of our SBIR grant Exploiting Synthetic Lethality of Hematopoietic Lineage Cells to Develop Novel Targets from the NIH. Rather than trying to identify potential drug targets in oncogenic hematopoietic cells, much of the effort for this project focuses on trying to develop a...

Therapeutic approaches using multiple drug combinations have become a standard treatment model for many types of cancer. Due to the tremendous genetic complexity and adaptive nature of most human malignancies, the use of multiple drugs acting on different targets increases the efficacy and helps thwart the...